Sight Sciences, Inc.
HealthcareNASDAQ:SGHT · NASDAQ Global Select
+$0.34 today
Vol 0.16M · Avg 0.27M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-60.1%
avg -13.8%
ROIC
-35.4%
avg -74.9%
ROA
-33.3%
avg -59.3%
Analysis
ROA is currently the strongest return metric at -33.3% versus its period average of -59.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Paul Badawi | Co-Founder, President, Chief Executive Officer & Director | $1.01M | — | 50 | $1.99M | 3.66% |
Alison Perry Bauerlein | Chief Operating Officer | $676,654.00 | — | 45 | $688,893.00 | 1.27% |
Jeremy Hayden | Chief Legal Officer & Corporate Secretary | $584,254.00 | — | 56 | $369,770.00 | 0.68% |
Steve R. Tamayo Jr. | Vice President and Chief Ethics & Compliance Officer | — | — | — | — | — |
James Rodberg | CFO & Treasurer | — | — | 42 | $230,939.00 | 0.42% |
David Badawi | Co-Founder, Chief Technology Officer & Director | — | — | 55 | $1.99M | 3.66% |
Brenton Taylor | Executive Vice President of Operations and R&D | — | — | 45 | $267,807.00 | 0.49% |
Mark Papini | Senior Vice President of Interventional Glaucoma | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$184,756.96
Sells
37
$2.22M
Net Sentiment
$2.04M
Net selling
Most Active
HAYDEN JEREMY B.
8 transactions
1–10 of 39
Analysis
Insiders reported 2 buys worth $184,756.96 and 37 sells worth $2.22M over the last 12 months. That adds up to net selling of $2.04M. HAYDEN JEREMY B. was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +45.1% | +6.4% (6yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +45.1% over three years. Forward estimates point to Revenue at +6.4% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cerus Corporation
NASDAQ:CERS
$512.94M
Viemed Healthcare, Inc.
NASDAQ:VMD
$400.62M
908 Devices Inc.
NASDAQ:MASS
$312.72M
Senseonics Holdings, Inc.
NASDAQ:SENS
$299.93M
Lifecore Biomedical, Inc.
NASDAQ:LFCR
$211.55M
Owens & Minor, Inc.
OMI
$207.07M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$151.72M
Quanterix Corporation
NASDAQ:QTRX
$146.03M
CVRx, Inc.
NASDAQ:CVRX
$133.48M
SANUWAVE Health, Inc.
NASDAQ:SNWV
$128.21M
Who manages SGHT?
Sight Sciences, Inc. (SGHT) lists 8 active executives. The top listed executive is Paul Badawi, Co-Founder, President, Chief Executive Officer & Director.
Are SGHT insiders buying or selling?
Recent insider activity shows net selling of $12.59M.
Explore More
Continue the stock analysis
Jump to another research area for this company.